Works matching IS 00126667 AND DT 2021 AND VI 81 AND IP 9
Results: 14
A Multicentric, Randomized, Controlled Phase III Study of Centhaquine (Lyfaquin®) as a Resuscitative Agent in Hypovolemic Shock Patients.
- Published in:
- Drugs, 2021, v. 81, n. 9, p. 1079, doi. 10.1007/s40265-021-01547-5
- By:
- Publication type:
- Article
Correction to: Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
Comment on: "Prior Treatment with Statins is Associated with Improved Outcomes of Patients with COVID-19: Data from the SEMI-COVID-19 Registry".
- Published in:
- 2021
- By:
- Publication type:
- Letter to the Editor
Correction to: Treatment Sequencing for Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
Comment on: "Post-Dialysis Parenteral Antimicrobial Therapy in Patients Receiving Intermittent High-Flux Haemodialysis".
- Published in:
- 2021
- By:
- Publication type:
- Letter to the Editor
Antimicrobial Lessons From a Large Observational Cohort on Intra-abdominal Infections in Intensive Care Units.
- Published in:
- Drugs, 2021, v. 81, n. 9, p. 1065, doi. 10.1007/s40265-021-01534-w
- By:
- Publication type:
- Article
Lazertinib: First Approval.
- Published in:
- Drugs, 2021, v. 81, n. 9, p. 1107, doi. 10.1007/s40265-021-01533-x
- By:
- Publication type:
- Article
Dasiglucagon: First Approval.
- Published in:
- Drugs, 2021, v. 81, n. 9, p. 1115, doi. 10.1007/s40265-021-01531-z
- By:
- Publication type:
- Article
Correction to: Inclisiran: First Approval.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis.
- Published in:
- Drugs, 2021, v. 81, n. 9, p. 985, doi. 10.1007/s40265-021-01528-8
- By:
- Publication type:
- Article
Failed, Interrupted, or Inconclusive Trials on Neuroprotective and Neuroregenerative Treatment Strategies in Multiple Sclerosis: Update 2015–2020.
- Published in:
- Drugs, 2021, v. 81, n. 9, p. 1031, doi. 10.1007/s40265-021-01526-w
- By:
- Publication type:
- Article
Evinacumab: First Approval.
- Published in:
- Drugs, 2021, v. 81, n. 9, p. 1101, doi. 10.1007/s40265-021-01516-y
- By:
- Publication type:
- Article
Immune Checkpoint Inhibition for Unresectable Malignant Pleural Mesothelioma.
- Published in:
- Drugs, 2021, v. 81, n. 9, p. 971, doi. 10.1007/s40265-021-01506-0
- By:
- Publication type:
- Article
A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes.
- Published in:
- Drugs, 2021, v. 81, n. 9, p. 1003, doi. 10.1007/s40265-021-01499-w
- By:
- Publication type:
- Article